|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/10/12 Hi Tech Pharmacal Co Inc 10-Q 7/31/12 64:3.3M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 319K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
4: EX-32 Certification -- §906 - SOA'02 HTML 18K
41: R1 Document and Entity Information HTML 38K
31: R2 Condensed Consolidated Balance Sheets HTML 120K
39: R3 Condensed Consolidated Balance Sheets HTML 39K
(Parenthetical)
43: R4 Condensed Consolidated Statements of Operations HTML 94K
(Unaudited)
58: R5 Consolidated Statements of Comprehensive Income HTML 34K
(Unaudited)
33: R6 Condensed Consolidated Statements of Cash Flows HTML 80K
38: R7 Basis of Presentation HTML 29K
28: R8 Business HTML 22K
20: R9 Revenue Recognition HTML 21K
59: R10 Net Income Per Share HTML 23K
45: R11 Accounts Receivable HTML 55K
44: R12 Inventory HTML 28K
49: R13 Property and Equipment HTML 33K
50: R14 Intangible Assets HTML 52K
48: R15 Long-Term Debt HTML 25K
51: R16 Freight Expense HTML 20K
40: R17 Stock-Based Compensation HTML 35K
42: R18 Product Divestitures HTML 22K
47: R19 Income Taxes HTML 26K
63: R20 Contingencies and Other Matters HTML 47K
54: R21 Recent Accounting Pronouncements HTML 28K
35: R22 Significant Customers and Concentration of Credit HTML 25K
Risk
46: R23 Fair Value Measurements HTML 37K
37: R24 Segment Information HTML 53K
15: R25 Accounts Receivable (Tables) HTML 51K
55: R26 Inventory (Tables) HTML 26K
60: R27 Property and Equipment (Tables) HTML 31K
24: R28 Intangible Assets (Tables) HTML 42K
23: R29 Stock-Based Compensation (Tables) HTML 29K
26: R30 Fair Value Measurements (Tables) HTML 27K
27: R31 Segment Information (Tables) HTML 44K
29: R32 Net Income Per Share (Details) HTML 19K
14: R33 Accounts Receivable (Details) HTML 28K
52: R34 Accounts Receivable (Details 1) HTML 32K
34: R35 Accounts Receivable (Details Textual) HTML 21K
36: R36 Inventory (Details) HTML 29K
18: R37 Property and Equipment (Details) HTML 34K
62: R38 Property and Equipment (Details Textual) HTML 29K
11: R39 Intangible Assets (Details) HTML 47K
30: R40 Intangible Assets (Details Textual) HTML 97K
57: R41 Long-Term Debt (Details) HTML 45K
17: R42 Freight Expense (Details) HTML 19K
22: R43 Stock-Based Compensation (Details) HTML 26K
25: R44 Stock-Based Compensation (Details Textual) HTML 42K
32: R45 Product Divestitures (Details) HTML 34K
13: R46 Income Taxes (Details) HTML 25K
19: R47 Contingencies and Other Matters (Details) HTML 65K
12: R48 Significant Customers and Concentration of Credit HTML 25K
Risk (Details)
56: R49 Fair Value Measurements (Details) HTML 23K
16: R50 Fair Value Measurements (Details Textual) HTML 20K
53: R51 Segment Information (Details) HTML 35K
61: XML IDEA XML File -- Filing Summary XML 91K
21: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 456K
5: EX-101.INS XBRL Instance -- hitk-20120731 XML 686K
7: EX-101.CAL XBRL Calculations -- hitk-20120731_cal XML 118K
8: EX-101.DEF XBRL Definitions -- hitk-20120731_def XML 233K
9: EX-101.LAB XBRL Labels -- hitk-20120731_lab XML 722K
10: EX-101.PRE XBRL Presentations -- hitk-20120731_pre XML 484K
6: EX-101.SCH XBRL Schema -- hitk-20120731 XSD 141K
64: ZIP XBRL Zipped Folder -- 0001193125-12-386176-xbrl Zip 82K
| EX-31.2 |
Exhibit 31.2
HI-TECH PHARMACAL CO., INC.
CERTIFICATION PURSUANT TO RULE 13A-14 OR 15D-14 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, WILLIAM PETERS, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Hi-Tech Pharmacal Co., Inc. |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: September 7, 2012
| By: | /s/ William Peters | |
| William Peters | ||
| Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/10/12 | None on these Dates | ||
| 9/7/12 | ||||
| For Period end: | 7/31/12 | |||
| List all Filings | ||||